Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement

Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement

Background: Zika virus (ZIKV), an arbovirus capable of causing neurological abnormalities, is a recognised human pathogen, for which a vaccine is required. As ZIKV antibodies can mediate antibody-dependent enhancement (ADE) of dengue virus (DENV) infection, a ZIKV vaccine must not only protect again...

Full description

Bibliographic Details
Main Authors:	Rahul Shukla, Rajgokul K. Shanmugam, Viswanathan Ramasamy, Upasana Arora, Gaurav Batra, Joshua A. Acklin, Florian Krammer, Jean K. Lim, Sathyamangalam Swaminathan, Navin Khanna
Format:	Article
Language:	English
Published:	Elsevier 2020-04-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396420301134

Similar Items

Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models
by: Rahul Shukla, et al.
Published: (2020-10-01)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
by: Arora Upasana, et al.
Published: (2012-07-01)

Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine
by: Rahul Shukla, et al.
Published: (2020-10-01)

Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
by: Swaminathan Sathyamangalam, et al.
Published: (2011-03-01)

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo
by: Rahul Shukla, et al.
Published: (2018-01-01)

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
by: Viswanathan Ramasamy, et al.
Published: (2018-01-01)

Dengue vaccine development: Global and Indian scenarios
by: Sathyamangalam Swaminathan, et al.
Published: (2019-07-01)

Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.
by: Shailendra Mani, et al.
Published: (2013-01-01)

Pichia pastoris-expressed Dengue 3 Envelope-based Virus-like Particles Elicit Predominantly Domain III-Focused High Titer Neutralizing Antibodies
by: Lav eTripathi, et al.
Published: (2015-09-01)

An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes
by: Swaminathan Sathyamangalam, et al.
Published: (2007-02-01)

<it>Escherichia coli</it>–expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen
by: Talha Sheikh M, et al.
Published: (2012-11-01)

Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses.
by: Anil Babu Korrapati, et al.
Published: (2012-01-01)

Evaluating the Safety of West Nile Virus Immunity During Congenital Zika Virus Infection in Mice
by: Joshua A. Acklin, et al.
Published: (2021-06-01)

Functional Analysis of Glycosylation of Zika Virus Envelope Protein
by: Camila R. Fontes-Garfias, et al.
Published: (2017-10-01)

Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice
by: Mei-Yu Chen, et al.
Published: (2020-04-01)

Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice.
by: Huabin Liang, et al.
Published: (2018-01-01)

Zika virus tropism during early infection of the testicular interstitium and its role in viral pathogenesis in the testes.
by: Konstantin A Tsetsarkin, et al.
Published: (2020-07-01)

Vaccine development of Zika envelope protein expressed by adenovirus-vector
by: Yang, Shao-Ping, et al.
Published: (2017)

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies
by: Emily N. Gallichotte, et al.
Published: (2019-09-01)

An interaction of Zika virus envelope fragments with serum antibodies derived from subjects after flavivirus infections
by: D. V. Shanshin, et al.
Published: (2020-04-01)

Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus
by: J. A. Swanstrom, et al.
Published: (2016-07-01)

Simultaneous detection of Human Immunodeficiency Virus 1 and Hepatitis B virus infections using a dual-label time-resolved fluorometric assay
by: Soukka Tero, et al.
Published: (2010-11-01)

LAMR1 restricts Zika virus infection by attenuating the envelope protein ubiquitination
by: Dingwen Hu, et al.
Published: (2021-01-01)

A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein
by: Anzhong Li, et al.
Published: (2018-08-01)

In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers
by: Stefan W. Metz, et al.
Published: (2017-07-01)

Deep Mutational Scanning to Map How Zika Envelope Protein Mutations Affect Viral Growth and Antibody Escape
by: Marion Sourisseau, et al.
Published: (2020-06-01)

Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora’s box?
by: Shannon A. Gunawardana, et al.
Published: (2018-12-01)

Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus
by: Mark J. Bailey, et al.
Published: (2019-04-01)

Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From Quillaja brasiliensis Enhances Anti-Zika Immune Responses, Including Neutralizing Antibodies and Splenocyte Proliferation
by: Samuel Cibulski, et al.
Published: (2021-03-01)

Zika virus envelope domain III recombinant proteins formulated with mucosal adjuvants for vaccine development
by: Wang, Wei-Bo, et al.
Published: (2018)

Development of Zika Virus DNA Vaccine Using Envelope Modified Baculoviral Gene Delivery System
by: Hanul Choi, et al.
Published: (2020-06-01)

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
by: Xinyi Wang, et al.
Published: (2019-10-01)

Incorporation of CD55 into the Zika Viral Envelope Contributes to Its Stability against Human Complement
by: Zahra Malekshahi, et al.
Published: (2021-03-01)

Simple high-cell density fed-batch technique for high-level recombinant protein production with <it>Pichia pastoris</it>: Application to intracellular production of Hepatitis B surface antigen
by: Ross Anton, et al.
Published: (2009-02-01)

A Recombinant Zika Virus Envelope Protein with Mutations in the Conserved Fusion Loop Leads to Reduced Antibody Cross-Reactivity upon Vaccination
by: Beatrice Sarah Berneck, et al.
Published: (2020-10-01)

Glucose-Regulated Protein 78 Interacts with Zika Virus Envelope Protein and Contributes to a Productive Infection
by: Jamie Royle, et al.
Published: (2020-05-01)

Zika Virus: An Emerging Worldwide Threat
by: Irfan A. Rather, et al.
Published: (2017-07-01)

Zika virus: A review with oral health implications
by: Ruchika Khanna, et al.
Published: (2017-01-01)

Expression, Purification, and Characterization of Anti-<i>Zika virus</i> Envelope Protein: Polyclonal and Chicken-Derived Single Chain Variable Fragment Antibodies
by: Pharaoh Fellow Mwale, et al.
Published: (2020-01-01)

Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
by: Young Chan Kim, et al.
Published: (2018-12-01)

Cannot write session to /tmp/vufind_sessions/sess_nssek7rpd7oe5836aslibq1sam